Adenocarcinoma of the prostate is the most commonly diagnosed malignancy
in men in the United States. It is estimated that, in 2005, 232 000 new
cases will be diagnosed and 30 350 men will die from this disease.1 Even though prostate-specific antigen (PSA) screening
has not been conclusively demonstrated to reduce mortality from prostate cancer,
this practice has been widely adopted in the United States. As a result, more
patients are being diagnosed at a younger age and with disease localized to
the prostate.1,2 For these patients,
radical prostatectomy (RP) and radiation therapy (RT) remain the mainstays
of curative therapy.3 Nevertheless, prostate
cancer remains primarily a disease of older men, many of whom have other serious
coexisting illnesses from which they may be far more likely to die. Thus,
it remains a major challenge for the clinician to identify which patients
need aggressive treatment and which do not.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature
Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 2
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.